Division of Prima Biomed Ltd./immutep SA
Latest From Immutep SA
Oncology focused startup EOC Pharma expects to develop an “exciting” pipeline in two years via the licensing model. The company is also seeking “constant” financing as it advances three drug candidates into the next stage in 2018, EOC CEO Xiaoming Zou tells Scrip in an interview.
Merck could pay up to $167m to try a new epigenetic target, which would build on its existing HDAC inhibitor. Meanwhile, Celgene buys epigenetics-focused Acetylon, which will spin out new company Regenacy to work with its lead HDAC6 inhibitor outside of oncology.
The Australian immuno-therapeutics developer Prima BioMed has had a change of focus in recent months since buying Paris-based Immutep in late 2014. Prima’s lead product used to be its CVac cancer vaccine, but it has now shifted strategic priority to an LAG-3 immune checkpoint receptor that came with the acquisition.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Prima Biomed Ltd.
- Senior Management
John B Hawken, Pres. & CEO
Frédéric Triebel, MD, PhD, Scientific & Medical Dir.
- Contact Info
Parc Club Orsay, 2
r. Jean Rostand
Orsay cedex, 91893
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.